knowledge -WSS

knowledge

author：knowledge 2025-09-11 06:21:29 - browse：75268

A young boy died in a trial for Pfizer’s experimental gene therapy for Duchenne muscular dystrophy, the company told patient advocates Tuesday.

The boy was enrolled in Daylight, a trial studying the treatment in boys aged 2 or 3. The boy had received the therapy early last year, Pfizer told the advocates in a note posted online by Parent Project Muscular Dystrophy.

Pfizer said the boy died of cardiac arrest, but that it was still working to understand what happened and the exact cause.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Lilly's Alzheimer's drug donanemab backed by FDA advisers

hotspot

focus

Wikipedia

WSS

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

AltruBio raises $225 million to develop ulcerative colitis drug

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Chemotherapy before breast cancer surgery might fuel metastasis

California wildfire smoke linked to 52,000 early deaths, study says

California wildfire smoke linked to 52,000 early deaths, study says

entertainment

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

STAT Virtual Event: ASCO Recap, Live!

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readers discuss the intersection of pregnancy and addiction

Heart attack and stroke risk calculators need revising

Empower primary care with adequate payments and technology

Jerome Adams on the need for new antivirals for Covid

Is it ever OK for doctors to lie to their patients?

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Warren pushes Witty on UnitedHealth's control over physicians

explore

New report analyzes digital physical therapy solutions' effectiveness

Crowdfunding for medical bills sidesteps core problem, author says

PBM executives asked to testify by House panel

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Pharma companies must ensure equitable access to obesity drugs

STAT Virtual Event: ASCO Recap, Live!

hotspot

focus

Wikipedia

entertainment